i think it's a bit of a "tomato, tomato" thing for me there. Pros and cons to both if you watch the videos with clinicians discussing it. Overall, they're indifferent about it, which says it's not much of a differentiator.
Ann: First patient imaged in Phase III AMPLIFY trial, page-16
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$3.91 |
Change
-0.280(6.68%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $4.28 | $4.38 | $3.83 | $18.80M | 4.704M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1846 | $3.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.92 | 9748 | 4 |
View Market Depth
| Last trade - 16.20pm 23/07/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |